<DOC>
	<DOCNO>NCT00718562</DOCNO>
	<brief_summary>This study evaluate efficacy safety nilotinib gastrointestinal stromal tumor patient fail imatinib sunitinib therapy .</brief_summary>
	<brief_title>Efficacy Safety AMN107 Patients With GastroIntestinal Stromal Tumors ( GIST ) Who Have Failed Both Imatinib Sunitinib</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Documented disease progression imatinib sunitinib therapy OR intolerance imatinib and/or sunitinib At least one measurable site disease CT/MRI scan PS≤2 Normal organ , electrolyte , bone marrow function Previous treatment nilotinib drug class target therapy Treatment cytotoxic and/or investigational drug ≤ 4 week prior study entry Impaired cardiac function Use coumarin derivative ( i.e . warfarin ) Women pregnant lactate Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>nilotinib</keyword>
	<keyword>AMN107</keyword>
	<keyword>Sunitinib</keyword>
	<keyword>Sunitinib malate</keyword>
	<keyword>Imatinib</keyword>
	<keyword>Imatinib mesylate</keyword>
	<keyword>Tyrosine</keyword>
</DOC>